To embed, copy and paste the code into your website or blog:
In the past week, Johnson & Johnson and Merck agreed to cooperate on production of the Janssen vaccine, and the Biden Administration used the Defense Production Act (DPA) to facilitate the arrangement. In addition, the GAO issued a report on the FDA’s inspection challenges. Please see details for these supply chain developments below:
On March 2, President Biden announced that Johnson & Johnson and Merck will cooperate to expand the production of the Janssen vaccine, and the Administration invoked the DPA to equip two Merck facilities to meet the standards necessary to manufacture the vaccine. He added that the Administration will continue to use the DPA to expedite critical materials in vaccine production, such as equipment, machinery, and supplies. He projected that the U.S. is on track to have enough vaccine supply for every adult in the U.S. by the end of May.
The Myeloma Crowd by The HealthTree Foundation Introduces Community Chapters and Events Platform
New Platform Reinvents Community Engagement for Patients with Multiple Myeloma
News provided by
Share this article
Share this article
SALT LAKE CITY, March 3, 2021 /PRNewswire/ The Myeloma Crowd, a division of The HealthTree Foundation that provides simplified patient education, advocacy and research funding for multiple myeloma, today announced the launch of its new Community Chapters & Events platform. This platform enables the Myeloma Crowd to build and host events organized by category or chapter, a new way to build and strengthen community among patients.
Each chapter in the platform addresses a specific facet of the myeloma patient experience and features events that pull expert advice, clinical research data, and patient-contributed anecdotal information on a wide range of topics that are important to patient outcomes. Current event chapters include Fitness for Myeloma,
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Adaptive Biotechnologies fourth quarter financial results conference call. [Operator instructions] I would now like to hand the conference over to your speaker today, Ms. Karina Calzadilla. Thank you.
Please go ahead.
Karina Calzadilla
Thank you, Jeff, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies fourth quarter and full-year 2020 earnings conference call. Earlier today, we issued a press release reporting Adaptive financial results for the fourth quarter and full year of 2020. The press release is available at adaptivebiotech.com.
We are conducting a live webcast of this call and will be referencing to a slide presentation that has been posted to the Investors section in our corporate website. During the call, management will make projections and other forward-looking statements within the meaning of federal securities laws regarding future events and the future
Earnings Scheduled For February 24, 2021 benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) Patients can conveniently opt to visit one of nearly 2,000 Labcorp sites or arrange for a mobile phlebotomy service at their home SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of T-Detect™ COVID, the first clinical T-cell based test to confirm recent or prior COVID-19 infection. In real-world studies, this first-in-class test outperformed leading antibody tests. Knowledge of prior COVID-19 infection is critically important for those who believe they may have been infected with the virus but have not been able to confirm a diagnosis. T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency U